
State of the Biopharmaceutical Industry 2023
Description
State of the Biopharmaceutical Industry 2023
Summary
In this report, GlobalData examines the business environment and trends that are going to shape the biopharmaceutical industry in 2023. The report highlights the most impactful emerging technologies, industry trends, regulatory trends, and microeconomic factors that are going to impact and dominate the industry throughout 2023.
Synopsis
Summary
In this report, GlobalData examines the business environment and trends that are going to shape the biopharmaceutical industry in 2023. The report highlights the most impactful emerging technologies, industry trends, regulatory trends, and microeconomic factors that are going to impact and dominate the industry throughout 2023.
Synopsis
- The pharmaceutical industry is set to face new challenges such as inflation in a post-COVID-19 world.
- Genomics, RWE, and IO will dominate as the most impactful trends in the biopharmaceutical industry next year.
- Among the most impactful trends, genomics will be the key focus in 2023.
- nflation and drug pricing pressures will be the top hindrances for pharmaceutical sector growth.
- Vertical integration, patent expiry of biologics, mega M&As, and ESG factors are anticipated to have the greatest positive impact on the pharmaceutical industry.
- Big data and AI will continue to dominate as transformational forces in the healthcare sector in 2023.
- Across the entire value chain, supply chains and manufacturing will be impacted the most by inflation in 2023.
- The biopharmaceutical industry is less optimistic about industry growth in the next 12 months compared to previous years.
- The pharmaceutical industry will continue to pursue its efforts to become more sustainable, with more companies committing to ESG strategies.
- Oncology, CNS, and infectious diseases will be the dominant areas for clinical trials initiated in 2023.
- Despite political rhetoric, COVID-19-induced pharmaceutical onshoring may not happen.
- While already met with skepticism by pharma, the Inflation Reduction Act will have to show if it can live up to its name.
- n 2023, economies and industries will continue to deal with inflationary pressures.
- nflation will disrupt pharmaceutical manufacturing and supply chains.
- Genomics is the trend that will continue to have the greatest impact on the pharmaceutical industry in 2023.
- nflation together with drug pricing and reimbursement-related concerns will be the leading impediment to industry growth.
- Vertical integration, patent expiry of biologics, mega M&As, and ESG factors will have the most positive impacts on industry.
- While less than in previous years, the biopharmaceutical industry is still optimistic about its growth in 2023.
- Benchmark the impact of major themes on the biopharmaceutical industry in 2023, including: emerging technologies, regulatory trends, macroeconomic trends, industry trends.
- dentify themes that will have the greatest positive or negative impact in 2023.
- Capture opinions on these themes from industry respondents.
- Assess the impact of COVID-19 on the biopharmaceutical sector.
- Explore how inflation will affect the pharmaceutical industry in 2023.
- Stay up to date with the major emerging technologies, regulatory, macroeconomic, and industry trends that will impact the pharmaceutical industry in 2023.
- Explore how the biopharmaceutical landscape has changed.
- dentify the most impactful anticipated regulatory approvals and drug launches in the industry in 2023.
- Gain insight into the regulatory and microeconomics trends that will have positive and negative effects on the biopharmaceutical industry.
- dentify emerging industry trends and innovations to gain a competitive advantage.
Table of Contents
110 Pages
- 1. Executive Summary
- 2. Study Design
- 3. Emerging Industry Trends
- 4. Emerging Regulatory and Macroeconomic Trends
- 5. Emerging Technologies
- 6. Industry Growth Prospects
- 7. Watch Outs
- 8. Summary of Key Findings
- 9. Appendix
- 10. Appendix
- 11. Contact Us
- List of Tables
- Table 1: Personalized medicine drugs expected to launch in 2023 for oncology indications
- Table 2: 12 drugs in pre-registration stage expected be approved by the end of 2022 and 2028 sales forecast
- List of Figures
- Figure 1: Respondent mix - geography
- Figure 2a: Respondent mix - seniority level
- Figure 2b: Respondent mix - company size
- Figure 3: Respondent mix - headquarter locations
- Figure 4: Top emerging pharmaceutical industry trend for 2023
- Figure 5: Top emerging pharmaceutical industry trend 2023 vs 2022
- Figure 6: Most impactful industry trends by region I
- Figure 7: Most impactful industry trends by region II
- Figure 8: Industry trends with the greatest impact on pharmaceutical industry in 2023
- Figure 9a: Number of trials initiated by phase of development, 2018-2022
- Figure 9b: Number of trials initiated by sponsor type, 2018-2022
- Figure 10a: Number of mRNA vaccine clinical trials by phase of development 2022
- Figure 10b: Number of mRNA vaccine clinical trials by sponsor type 2022
- Figure 11: Number of RWE trials by sponsor type and year
- Figure 12a: Number of ICI indications by phases of development
- Figure 12b: Number of CART-T indications by phases of development
- Figure 13: How companies addressed clinical trial disruptions due to COVID-19 pandemic 2020-2022
- Figure 14: Company usage of DCT before COVID-19
- Figure 15: Percentage of clinical trials using DCT components
- Figure 16: Main benefits associated with using DTx
- Figure 17a: Microbiome agents in development in each therapy area
- Figure 17b: Percent microbiome agents in development for each indication - Infectious disease
- Figure 17c: Percent microbiome agents in development for each indication - gastrointestinal
- Figure 17d: Number of clinical trials initiated per year with microbiome-targeting therapeutics
- Figure 18: Regenerative medicine market 2021-2028
- Figure 19: Biggest barrier associated with a wider implementation of electronic healthcare records
- Figure 20: Regulatory and macroeconomic trends with the greatest positive and negative impact on pharmaceutical industry in 2023
- Figure 21: Impact of emerging regulatory and macroeconomic trends on pharmaceutical industry in 2023
- Figure 22: Change in average drug price 2017-2021
- Figure 23: Usage of IRP
- Figure 24a: Rise of pharmaceutical prices in 2023
- Figure 24b: Rise of pharmaceutical prices in 2023 by region
- Figure 25: Factors driving government endorsement of real-terms drug price increases
- Figure 26a: Rheumatoid arthritis: biosimilar sales forecast, 7MM and Australia, 2019-2029
- Figure 26b: Rheumatoid arthritis: average biosimilar prescription, 7MM and Australia, 2019-2029
- Figure 27: Number of clinical trials by year
- Figure 28: Impact of emerging regulatory and macroeconomic trends on pharmaceutical industry in 2023
- Figure 29: Top positive emerging regulatory and macroeconomic trends - highest positive scores by geography
- Figure 30: Top positive emerging regulatory and macroeconomic trends - high positive vs low negative scores
- Figure 31: Impact of emerging technologies on pharmaceutical industry in 2023
- Figure 32: Impact of emerging technologies on pharmaceutical industry in 2020-2023
- Figure 33: Impact on investment in emerging technologies by COVID-19 outbreak
- Figure 34: Impact on investment in emerging technologies by inflation and rising costs during next 12 months
- Figure 35: Emerging technologies with the greatest impact on pharmaceutical industry in 2023
- Figure 36: Top five emerging technologies 2020-2023
- Figure 37: Job analytic on AI and big data
- Figure 38: Factors hinder digital transformation at organizations
- Figure 39: Sentiment on industry’s growth during next 12 months
- Figure 40: Sentiment on industry’s growth during next 12 months, 2020-2023
- Figure 41: Inflation impact on pharmaceutical value chain
- Figure 42: Inflation impact on pharmaceutical value chain by region
- Figure 43a: Deflation outlook
- Figure 43b: Deflation outlook by region
- Figure 44: Economic outlook of major markets
- Figure 45a: HCPs’ opinions on whether the number of patients stopping or postponing treatments has increased
- Figure 45b: Initiatives that could help to reduce inflation in the healthcare
- Figure 46: HCPs’ thoughts on IRA’s ability to reduce drug prices
- Figure 47: If pharma industry is doing enough to be more environmentally sustainable 2022 vs 2021
- Figure 48a: Planned clinical trials in 2023 by phase
- Figure 48b: Top industry sponsors for planned clinical trials in 2023
- Figure 49a: Top countries for planned clinical trials in 2023 by number and phase
- Figure 49b: Drug types for planned clinical trials in 2023 by phase
- Figure 50a: Top therapy areas for planned clinical trials to be initiated in 2023
- Figure 50b: Top indications for planned clinical trials to be initiated in 2023
- Figure 51a: Projected trial completion in 2023 by phase
- Figure 51b: Top industry sponsors for trials projected to be completed in 2023
- Figure 52: Top 10 prescription drugs - 2022 vs 2023
- Figure 53: Top 10 therapy areas - 2022 vs 2023
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.